GGrantIndex
← Leaderboards

Scott C Kogan

University Of California San Francisco

$5,271,284
Attributed
$7,030,925
Total exposure
5
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $864.1K · FY200518
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$7,030,925 · 5

By mechanism

R01$5,839,467 · 2
K08$508,680 · 1
R21$379,680 · 1
P50$303,098 · 1

Top collaborators

Most similar at University Of California San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Leukemia

Research focus

LeukemiaMouse ModelCellsImmuneLeukemogenesisGene ExpressionCarcinogenesisBirthEtv6 GeneInvestigationMediator Of Activation ProteinMalignant NeoplasmsResponseB-LymphocytesGeneticRunx1 GeneAnimal ModelDiagnosisDisease /Disorder ModelComplementCytokineEffective TherapyImmune SystemEnvironment

Grant awards (26)

Impact of low IL-10 levels at birth and leukemia risk$602,331
R01 · FY2018 · CA · contact PI
Core C - Mouse Model Service Core$49,789
P50 · FY2018 · ES · contact PI
Impact of low IL-10 levels at birth and leukemia risk$606,390
R01 · FY2017 · CA · contact PI
Core C - Mouse Model Service Core$57,294
P50 · FY2017 · ES · contact PI
Impact of low IL-10 levels at birth and leukemia risk$624,355
R01 · FY2016 · CA
Core C - Mouse Model Service Core$62,910
P50 · FY2016 · ES · contact PI
Impact of low IL-10 levels at birth and leukemia risk$639,604
R01 · FY2015 · CA
Core C - Mouse Model Service Core$73,561
P50 · FY2015 · ES · contact PI
Core C - Mouse Model Service Core$59,544
P50 · FY2015 · ES · contact PI
Impact of low IL-10 levels at birth and leukemia risk$666,922
R01 · FY2014 · CA
Impact of B-Cell Lineage on Progression of B-Acute Lymphoblastic Leukemia$197,209
R21 · FY2014 · CA
Molecular Mechanisms of Leukemogenesis by PMLRAR alpha$268,969
R01 · FY2013 · CA · contact PI
Impact of B-Cell Lineage on Progression of B-Acute Lymphoblastic Leukemia$182,471
R21 · FY2013 · CA
Molecular Mechanisms of Leukemogenesis by PMLRAR alpha$286,137
R01 · FY2012 · CA · contact PI
Molecular Mechanisms of Leukemogenesis by PMLRAR alpha$274,132
R01 · FY2011 · CA · contact PI
Molecular Mechanisms of Leukemogenesis by PMLRAR alpha$288,083
R01 · FY2010 · CA · contact PI
Molecular Mechanisms of Leukemogenesis by PMLRAR alpha$296,298
R01 · FY2009 · CA · contact PI
Molecular Mechanisms of Leukemogenesis by PMLRAR alpha$281,086
R01 · FY2006 · CA · contact PI
Molecular Mechanisms of Leukemogenesis by PMLRAR alpha$287,850
R01 · FY2005 · CA
Molecular Mechanisms of Leukemogenesis by PMLRAR alpha$287,850
R01 · FY2004 · CA
Molecular Mechanisms of Leukemogenesis by PMLRAR alpha$215,532
R01 · FY2003 · CA
PATHOGENESIS AND THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA$127,170
K08 · FY2003 · CA
Molecular Mechanisms of Leukemogenesis by PMLRAR alpha$213,928
R01 · FY2002 · CA
PATHOGENESIS AND THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA$127,170
K08 · FY2002 · CA
PATHOGENESIS AND THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA$127,170
K08 · FY2001 · CA
PATHOGENESIS AND THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA$127,170
K08 · FY2000 · CA